[{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arrivo BioVentures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Inapplicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arrivo BioVentures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Inapplicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Orlando Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.050000000000000003,"dosageForm":"Oral Capsule","sponsorNew":"Arrivo BioVentures \/ Orlando Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Orlando Health Ventures"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Firefly Neuroscience","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arrivo BioVentures \/ Arrivo BioVentures","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Arrivo BioVentures"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arrivo BioVentures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Inapplicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RABI-767","moa":"Lipase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrivo BioVentures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Arrivo BioVentures

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : SP-624 is a first-in-class SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of patients with major depressive disorder.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : SP-624

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Recipient : Firefly Neuroscience

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : SP-624 is a novel SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of major depressive disorder.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 10, 2024

                          Lead Product(s) : SP-624

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : RABI-767 is a novel, small molecule lipase inhibitor that halts the highly toxic cascade of fat necrosis, systemic toxicity, organ failure and mortality in severe acute pancreatitis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 15, 2024

                          Lead Product(s) : RABI-767

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : SP-624 is a novel SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of major depressive disorder.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 16, 2024

                          Lead Product(s) : SP-624

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Arrivo will advance its first-in-class treatment for major depressive disorder, SP-624, through Phase 2b/3 trial and complete a Phase 2 study with its novel treatment to prevent patients with pancreatitis advancing to severe acute pancreatitis, RABI-767.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 29, 2023

                          Lead Product(s) : SP-624

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Orlando Health Ventures

                          Deal Size : $45.2 million

                          Deal Type : Series B Financing

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : SP-624 has a novel epigenetic mechanism to enhance neuroplasticity in brain regions involved in depression, namely the hippocampus and prefrontal cortex.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 26, 2022

                          Lead Product(s) : SP-624

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank